Inhibiting the compensatory elevation of SLC7A11 protein translation enhances proteasome inhibitor carfilzomib-induced ferroptosis by inhibiting FTH1 and GPX4 expression in B-acute lymphoblastic leukemia

The proteasome inhibitor carfilzomib (CFZ) exerts anti-leukemic activity through multiple mechanisms. Ferroptosis, a nonapoptotic, iron-dependent form of cell death, has emerged as a promising therapeutic strategy for cancer therapy. However, whether CFZ induces ferroptosis in B acute lymphoblastic leukemia (B-ALL) remains unclear. Here, we showed that CFZ markedly induced ferroptosis, as evidenced by increased levels of lipid reactive oxygen species (ROS), Fe²⁺, and malondialdehyde (MDA), along with decreased glutathione (GSH) levels. CFZ induced ferroptosis by reducing ferritin heavy chain (FTH1) and glutathione peroxidase-4 (GPX4) protein levels. However, CFZ induced a rapid compensatory increase in SLC7A11 protein levels. Mechanistically, CFZ reduced polysome fractions and inhibited global translation by inducing phosphorylation of eukaryotic translation initiation factor 2 subunit alpha (p-eIF2α), which is a marker of endoplasmic reticulum stress (ERS). However, CFZ paradoxically enhanced SLC7A11 translation efficiency through a compensatory mechanism. Knockdown of eIF2α attenuated CFZ-induced upregulation of SLC7A11, indicating that CFZ increased SLC7A11 expression by inducing ERS. Pharmacological and genetic inhibition of SLC7A11 further exacerbated CFZ-induced ferroptosis, suggesting that compensatory elevation of SLC7A11 weakened CFZ-induced anti-ferroptotic effects. Notably, CFZ synergized with ferroptosis inducer disulfiram (DSF) to induce ferroptosis. Furthermore, CFZ plus DSF significantly inhibited leukemic cell infiltration and prolonged overall survival (OS) in the BCR-ABL (P190)-driven B-ALL mouse model compared with either agent alone. Finally, CFZ induced ferroptosis in primary B-ALL patient samples. In conclusion, our findings demonstrate that blocking the compensatory SLC7A11 upregulation enhances CFZ-induced ferroptosis. Combined CFZ and DSF therapy represents a promising ferroptosis-based therapeutic strategy for B-ALL patients.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-18
DOI
https://doi.org/10.5281/zenodo.24344687
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Inhibiting the compensatory elevation of SLC7A11 protein translation enhances proteasome inhibitor carfilzomib-induced ferroptosis by inhibiting FTH1 and GPX4 expression in B-acute lymphoblastic leukemia

Liuzhi Shi, 林清臣, XiaoFei He, Xuanyu Yu et al.
Zenodo (CERN European Organization for Nuclear Research)
Ferroptosis and cancer prognosis
article

Inhibiting the compensatory elevation of SLC7A11 protein translation enhances proteasome inhibitor carfilzomib-induced ferroptosis by inhibiting FTH1 and GPX4 expression in B-acute lymphoblastic leukemia

Liuzhi Shi, 林清臣, XiaoFei He, Xuanyu Yu, Shirui Yu, Shixin Zhang, Qiulin Wu, Chen Xinyao, Zhou Bin, Gao Shenmeng, Wang Hangu, Zuo Liping, Chen Haoye, Zhang Xinyu, Ye Haige
article en

Abstract

The proteasome inhibitor carfilzomib (CFZ) exerts anti-leukemic activity through multiple mechanisms. Ferroptosis, a nonapoptotic, iron-dependent form of cell death, has emerged as a promising therapeutic strategy for cancer therapy. However, whether CFZ induces ferroptosis in B acute lymphoblastic leukemia (B-ALL) remains unclear. Here, we showed that CFZ markedly induced ferroptosis, as evidenced by increased levels of lipid reactive oxygen species (ROS), Fe²⁺, and malondialdehyde (MDA), along with decreased glutathione (GSH) levels. CFZ induced ferroptosis by reducing ferritin heavy chain (FTH1) and glutathione peroxidase-4 (GPX4) protein levels. However, CFZ induced a rapid compensatory increase in SLC7A11 protein levels. Mechanistically, CFZ reduced polysome fractions and inhibited global translation by inducing phosphorylation of eukaryotic translation initiation factor 2 subunit alpha (p-eIF2α), which is a marker of endoplasmic reticulum stress (ERS). However, CFZ paradoxically enhanced SLC7A11 translation efficiency through a compensatory mechanism. Knockdown of eIF2α attenuated CFZ-induced upregulation of SLC7A11, indicating that CFZ increased SLC7A11 expression by inducing ERS. Pharmacological and genetic inhibition of SLC7A11 further exacerbated CFZ-induced ferroptosis, suggesting that compensatory elevation of SLC7A11 weakened CFZ-induced anti-ferroptotic effects. Notably, CFZ synergized with ferroptosis inducer disulfiram (DSF) to induce ferroptosis. Furthermore, CFZ plus DSF significantly inhibited leukemic cell infiltration and prolonged overall survival (OS) in the BCR-ABL (P190)-driven B-ALL mouse model compared with either agent alone. Finally, CFZ induced ferroptosis in primary B-ALL patient samples. In conclusion, our findings demonstrate that blocking the compensatory SLC7A11 upregulation enhances CFZ-induced ferroptosis. Combined CFZ and DSF therapy represents a promising ferroptosis-based therapeutic strategy for B-ALL patients.

Zenodo (CERN European Organization for Nuclear Research)
Ferroptosis and cancer prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon